Sildenafil during the 2nd and 3rd Trimester of Pregnancy: Trials and Tribulations.

Abstract

Sildenafil, a phosphodiesterase 5 inhibitor with a vasodilatory and anti-remodeling effect, has been investigated concerning various conditions during pregnancy. Per indication, we herein review the rationale and the most relevant experimental and clinical studies, including systematic reviews and meta-analyses, when available. Indications for using sildenafil during the second and third trimester of pregnancy include maternal pulmonary hypertension, preeclampsia, preterm labor, fetal growth restriction, oligohydramnios, fetal distress, and congenital diaphragmatic hernia. For most indications, the rationale for administering prenatal sildenafil is based on limited, equivocal data from in vitro studies and rodent disease models. Clinical studies report mild maternal side effects and suggest good fetal tolerance and safety depending on the underlying pathology.

• Authors: Felix Rafael De Bie, David Basurto, Sailesh Kumar, Jan Deprest, Francesca Maria Russo
• Journal: International journal of environmental research and public health (Int J Environ Res Public Health) Vol. 19 Issue 18 (09 06 2022) ISSN: 1660-4601 [Electronic] Switzerland
• PMID: 36141480 (Publication Type: Journal Article, Review)

Chemical References

• Phosphodiesterase 5 Inhibitors
• Sildenafil Citrate

Topics

• Female
• Fetal Growth Retardation
• Hernias, Diaphragmatic, Congenital (chemically induced, drug therapy)
• Humans
• Hypertension, Pulmonary
• Phosphodiesterase 5 Inhibitors (pharmacology, therapeutic use)
• Pre-Eclampsia (chemically induced)
• Pregnancy
• Sildenafil Citrate (pharmacology, therapeutic use)